A detailed history of Black Rock Inc. transactions in Applied Therapeutics Inc. stock. As of the latest transaction made, Black Rock Inc. holds 6,569,787 shares of APLT stock, worth $61 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,569,787
Previous 989,277 564.1%
Holding current value
$61 Million
Previous $6.73 Million 356.07%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$4.04 - $6.37 $22.5 Million - $35.5 Million
5,580,510 Added 564.1%
6,569,787 $30.7 Million
Q1 2024

May 10, 2024

BUY
$2.25 - $7.4 $1.04 Million - $3.41 Million
461,391 Added 87.4%
989,277 $6.73 Million
Q4 2023

Feb 13, 2024

BUY
$1.84 - $3.35 $264,763 - $482,041
143,893 Added 37.47%
527,886 $1.77 Million
Q3 2023

Nov 13, 2023

SELL
$1.26 - $2.77 $17,681 - $38,871
-14,033 Reduced 3.53%
383,993 $956,000
Q2 2023

Aug 11, 2023

BUY
$0.77 - $1.8 $96,261 - $225,027
125,015 Added 45.79%
398,026 $509,000
Q1 2023

May 12, 2023

SELL
$0.75 - $1.21 $15,577 - $25,131
-20,770 Reduced 7.07%
273,011 $221,000
Q4 2022

Feb 13, 2023

SELL
$0.54 - $1.12 $126,503 - $262,376
-234,265 Reduced 44.36%
293,781 $223,000
Q3 2022

Nov 14, 2022

BUY
$0.86 - $1.55 $33,632 - $60,617
39,108 Added 8.0%
528,046 $490,000
Q2 2022

Aug 12, 2022

SELL
$0.76 - $2.64 $664,593 - $2.31 Million
-874,465 Reduced 64.14%
488,938 $463,000
Q1 2022

May 12, 2022

BUY
$1.48 - $6.22 $96,010 - $403,503
64,872 Added 5.0%
1,363,403 $2.88 Million
Q4 2021

Feb 10, 2022

BUY
$8.77 - $18.29 $50,111 - $104,509
5,714 Added 0.44%
1,298,531 $11.6 Million
Q3 2021

Nov 09, 2021

SELL
$13.54 - $22.06 $261,118 - $425,427
-19,285 Reduced 1.47%
1,292,817 $21.5 Million
Q2 2021

Aug 11, 2021

BUY
$14.05 - $25.04 $18.4 Million - $32.9 Million
1,312,102 New
1,312,102 $27.3 Million

Others Institutions Holding APLT

About Applied Therapeutics Inc.


  • Ticker APLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,700
  • Market Cap $446M
  • Description
  • Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study...
More about APLT
Track This Portfolio

Track Black Rock Inc. Portfolio

Follow Black Rock Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.